PDS Biotechnology Corp
Change company Symbol lookup
Select an option...
PDSB PDS Biotechnology Corp
BAC Bank of America Corp
XLF Financial Select Sector SPDR® Fund
FRAN Francesca's Holdings Corp
ED Consolidated Edison Inc
BIIB Biogen Inc
CNF CNFinance Holdings Ltd
LVS Las Vegas Sands Corp
AZDDQ Azure Dynamics Corp
$DWACSMN Dorsey Wright Country Stock NTRIndex
Go

Health Care : Biotechnology | Small Cap Value
Company profile

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Closing Price
$1.67
Day's Change
-0.05 (-2.91%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.78
Day's Low
1.64
Volume
(Light)
Volume:
590,425

10-day average volume:
4,251,940
590,425
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.